2012

• Par to Acquire 14 Generic Products: Purchase of Products to Be Completed Following Close of Watson's Acquistion of Actavis
• Paul V. Campanelli named Chief Executive Officer of Par Pharmaceutical Companies, Inc.™
• Par Announces Completion Of Acquisition By TPG
• Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
• Par Pharmaceutical Completes Acquisition of Edict Pharmaceuticals

2011

• Par Pharmaceutical Completes Acquisition of Anchen

2010

• Strativa launches Oravig™ (miconazole) buccal tablets
• Par Pharmaceutical begins shipment of Generic Zegerid®
• Strativa receives FDA approval for Oravig™ (miconazole) buccal tablets
• Strativa receives FDA approval for Zuplenz® (ondansetron) Oral Soluble Film
• Par obtains exclusive rights to market and distribute Generic Zetia® in the U.S.

2009

• Par Pharmaceutical receives approval for and begins shipping generic Ultram® ER
• Par Pharmaceutical receives approval to market generic Starlix® and begin shipment of the product
• FDA accepts Strativa Pharmaceuticals’ new drug application for ondansetron oral soluble film
• FDA accepts BioAlliance Pharma SA’s new drug application for Oravig, miconazole mucoadhesive buccal tablets (MBT) to treat oropharyngeal candidiasis (OPC); under a licensing agreement, Strativa is the exclusive US distributor
• Par begins shipment of Generic Risperdal® M-Tab
• Aveva Drug Delivery Systems has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for a clonidine transdermal system (Clonidine TDS).
• Strativa Pharmaceuticals acquires worldwide rights to Nascobal® (Cyanocobalamin, USP) Nasal Spray from QOL Medical

2008

• Par Pharmaceutical Companies, Inc. resizes generic unit to optimize current product portfolio and strong pipeline
• Par Pharmaceutical receives final approval to market generic Marinol® C-III (Dronabinol) Capsules
• Par Pharmaceutical acquires generic Imitrex® Injection (sumatriptan succinate injection) from Spectrum Pharmaceuticals and begins shipment of the product
• Strativa Pharmaceuticals in-licenses ONCONASE® from Alfacell Corporation and oral thin film formulation of ondansetron from MonoSol Rx®

2007

• Par Pharmaceutical Companies, Inc. introduces Strativa Pharmaceuticals, as its renamed Proprietary Products Division, for proprietary specialty pharmaceuticals
• Par Pharmaceutical introduces five new generic products and, with its partner companies, files 10 ANDAs including 7 potential first-to-files
• Par Pharmaceutical receives approval for and launches propranolol extended release capsules, a generic version of Inderal LA®. Par’s was the first generic version of this modified release product to be approved and reach the marketplace
• Par Pharmaceutical Companies, Inc. in-licenses three proprietary products in development, Zensana™ (ondansetron HCl) Oral Spray, MMBT (miconazole Lauriad®) and pafuramidine maleate, each aimed at building the company's portfolio of supportive care therapies

2006

• Par Pharmaceutical introduces nine new generic products and, with its partner companies, files six ANDAs including five potential first-to-files
• Par Pharmaceutical begins shipment of generic Toprol-XL® (metoprolol succinate extended release 25 mg tablets)
• Patrick G. LePore named President and Chief Executive Officer of Par Pharmaceutical Companies, Inc.™
• Par Pharmaceutical begins shipment of generic Flonase® (fluticasone) Nasal Spray

2005

• Par Pharmaceutical Companies launches its proprietary products division with John MacPhee named President and specialty brand Megace® ES (megestrol acetate) as its first product
• Par Pharmaceutical receives approval to market Megace® ES (megestrol acetate)
• Par Pharmaceutical introduces 15 new generic products and, with its partner companies, files 17 ANDAs including 1 potential first-to-file
• Par Pharmaceutical receives approval and 180-day marketing exclusivity for generic Ultracet®

2004

• Par Pharmaceutical introduces 17 new generic products and, with its partner companies, files 24 new ANDAs, 1 first-to-file and 2 NDAs

2003

• Par Pharmaceutical begins shipment of generic Paxil® (paroxetine HCl immediate release tablets)

2002

• Par Pharmaceutical wins prestigious DIANA Award from Healthcare Distribution Management Association

2001

• Par Pharmaceutical begins shipment of generic Megace® and generic Prozac® 40 mg capsules

1987

• Par Pharmaceutical Companies, Inc. (PRX) is listed on New York Stock Exchange

1978

• Par Pharmaceutical is founded as a generics pharmaceutical products company